<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02933021</url>
  </required_header>
  <id_info>
    <org_study_id>HAF 01</org_study_id>
    <secondary_id>193751</secondary_id>
    <secondary_id>16/EE/0071</secondary_id>
    <nct_id>NCT02933021</nct_id>
  </id_info>
  <brief_title>Unravel MGUS (Monoclonal Gammopathy of Unknown Significance)</brief_title>
  <official_title>Understanding Monoclonal Gammopathy of Unknown Significance (MGUS): A Research Study to Investigate the Functional Consequences of Paraprotein Production in MGUS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Human Antibody Factory Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Human Antibody Factory Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to investigate the functional consequences of paraprotein production in MGUS
      (Monoclonal gammopathy of unknown significance).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Monoclonal gammopathy of unknown significance (MGUS) is a common haematological condition. It
      is characterised by proliferation of a B lymphocyte clone and it's associated antibody
      (paraprotein). In most cases there are no clinical symptoms, however, in a small number of
      individuals there may be an interaction of the paraprotein with a molecule expressed by the
      body (self antigen). This can have effects on the normal function of this molecule and/or
      cause disease.

      The study aims to investigate the functional consequences of paraprotein production in MGUS.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical assays (i.e. Haematology, biochemistry, immunology, endocrinology): to capture the number of assay phenotypes that are statistically different from normal ranges.</measure>
    <time_frame>Up to 4 years from study start</time_frame>
    <description>For clinical assays with defined normal ranges, we will capture those results that are significantly outside of normal range. For those with no generally accepted normal ranges, the results will be compared against results from the other individuals.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quantitative analysis of cytokine/chemokines, measured by multiplex immunoassays .</measure>
    <time_frame>Up to 4 years from study start</time_frame>
    <description>The results will be compared against results from the other individuals.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Metabolic profile of metabolites in blood measured by gas chromatography-mass spectrometry and nuclear magnetic resonance spectrometry.</measure>
    <time_frame>Up to 4 years from study start</time_frame>
    <description>the data points and over all profiles will be compared against results from the other individuals.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The number of conversions to multiple myeloma</measure>
    <time_frame>Up to 4 years from study start</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Monoclonal Gammopathy of Unknown Significance</condition>
  <arm_group>
    <arm_group_label>All participants</arm_group_label>
    <description>Nurse visit for blood sample, questionnaire and phone call</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood sample taken</intervention_name>
    <arm_group_label>All participants</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Answering a lifestyle questionnaire</intervention_name>
    <arm_group_label>All participants</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Phone call from researcher</intervention_name>
    <description>To enquire about status of participants monoclonal gammopathy of unknown significance, and whether there has been progression to multiple myeloma.</description>
    <arm_group_label>All participants</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma and serum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study will recruit patients diagnosed with monoclonal gammopathy of unknown
        significance.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Participants must comply with the following criteria in order to be eligible for the study:

          -  Be aged â‰¥18 years at the time the informed consent form is signed

          -  Have a confirmed and documented Monoclonal Gammopathy of Unknown Significance (MGUS)
             diagnosis

          -  Read and understood the participant information sheet, and signed an Institutional
             Review Board/Independent Ethics Committee (IRB/IEC) approved informed consent form
             prior to any study- specific evaluation

        Exclusion Criteria:

        Participants will be excluded from joining the study if they match any of the criteria
        below:

          -  Pre-existing diagnosis of myeloma/lymphoma

          -  Participation in a therapeutic clinical study within 28 days or (5 half lives,
             whichever is longer) of enrolment or during this study

          -  Any other reason the Clinical Investigator (CI) considers the participant should not
             join the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tilly Sharp</last_name>
    <role>Principal Investigator</role>
    <affiliation>Total Scientific Limited</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gayle Chapman</last_name>
    <phone>+44(0)1223 804507</phone>
    <email>gayle@unravelmgus.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jun Thompson</last_name>
    <phone>+44(0)1223 804507</phone>
    <email>jun@unravelmgus.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Royal Berkshire Hospital</name>
      <address>
        <city>Reading</city>
        <state>Berkshire</state>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Team Leader</last_name>
      <phone>+44 (0)118 322 7690</phone>
    </contact>
    <investigator>
      <last_name>Pratap Neelakantan, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Addenbrookes Hospital</name>
      <address>
        <city>Cambridge</city>
        <state>Cambridgeshire</state>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PA to Charles Crawley, Dr</last_name>
      <phone>+44 (0)1223 254978</phone>
    </contact>
    <investigator>
      <last_name>Charles Crawley, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>George Follows, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tilly Sharp, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Torbay Hospital</name>
      <address>
        <city>Torquay</city>
        <state>Devon</state>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cancer Research Team Leader</last_name>
      <phone>+44 (0)1803 656623</phone>
    </contact>
    <investigator>
      <last_name>Heather Eve, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Heartlands Hospital</name>
      <address>
        <city>Birmingham</city>
        <state>West Midlands</state>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lead Research Nurse</last_name>
      <phone>+44 (0)121 424 1614</phone>
    </contact>
    <investigator>
      <last_name>Anand Lokare, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St James's Hospital</name>
      <address>
        <city>Leeds</city>
        <state>West Yorkshire</state>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Assistant</last_name>
      <phone>+44 (0)113 206 8483</phone>
    </contact>
    <investigator>
      <last_name>Gordon Cook, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guy's and St. Thomas' Hospital</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Co-ordinator</last_name>
      <phone>+44 (0)2071887188</phone>
    </contact>
    <investigator>
      <last_name>Matthew Streetly, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Freeman Hospital</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Officer</last_name>
      <phone>+44 (0)1912139288</phone>
    </contact>
    <investigator>
      <last_name>Graham Jackson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nottingham City Hospital</name>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Nurse</last_name>
      <phone>+44 (0)115 969 1169</phone>
    </contact>
    <investigator>
      <last_name>Cathy Williams, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rotherham Hospital</name>
      <address>
        <city>Rotherham</city>
        <zip>S602UD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lead Research Nurse</last_name>
      <phone>+44 (0)1709 426066</phone>
    </contact>
    <investigator>
      <last_name>Arun Alfred, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 15, 2016</study_first_submitted>
  <study_first_submitted_qc>October 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2016</study_first_posted>
  <last_update_submitted>September 22, 2017</last_update_submitted>
  <last_update_submitted_qc>September 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MGUS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paraproteinemias</mesh_term>
    <mesh_term>Monoclonal Gammopathy of Undetermined Significance</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

